COCRYSTAL PHARMA, INC. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
COCRYSTAL PHARMA, INC. (COCP) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $2.18 million as of 2020-12-31, per its 10-K filed 2021-03-17.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2021-03-17
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.18M.
- 2019-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.00M.
- 2018-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $2.02M.
- 2017-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $1.79M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2020-12-31 | $2.18M 10-K · filed 2021-03-17 |
| 2019-12-31 | $2.00M 10-K · filed 2021-03-17 |
| 2018-12-31 | $2.02M 10-K · filed 2020-03-27 |
| 2017-12-31 | $1.79M 10-K · filed 2019-04-01 |
| 2016-12-31 | $1.39M 10-K · filed 2018-03-21 |
| 2015-12-31 | $972.00K 10-K · filed 2017-03-31 |
| 2014-12-31 | $835.00K 10-K · filed 2016-03-15 |
| 2013-12-31 | $840.00K 10-K · filed 2015-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |